Cargando…

Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review

OBJECTIVE: To aid trialists, systematic reviewers and others, we evaluated the degree of standardisation of control measure reporting that has occurred in atrial fibrillation (AF) and venous thromboembolism (VTE) studies since 2000; and attempted to determine whether the prior recommendation of repo...

Descripción completa

Detalles Bibliográficos
Autores principales: Mearns, Elizabeth S, Hawthorne, Jessica, Song, Ju-Sung, Coleman, Craig I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067815/
https://www.ncbi.nlm.nih.gov/pubmed/24951111
http://dx.doi.org/10.1136/bmjopen-2014-005379
_version_ 1782322341004443648
author Mearns, Elizabeth S
Hawthorne, Jessica
Song, Ju-Sung
Coleman, Craig I
author_facet Mearns, Elizabeth S
Hawthorne, Jessica
Song, Ju-Sung
Coleman, Craig I
author_sort Mearns, Elizabeth S
collection PubMed
description OBJECTIVE: To aid trialists, systematic reviewers and others, we evaluated the degree of standardisation of control measure reporting that has occurred in atrial fibrillation (AF) and venous thromboembolism (VTE) studies since 2000; and attempted to determine whether the prior recommendation of reporting ≥2 measures per study has been employed. DESIGN: Systematic review. SEARCH STRATEGY: We searched bibliographic databases (2000 to June 2013) to identify AF and VTE studies evaluating dose-adjusted vitamin K antagonists (VKAs) and reporting ≥1 control measure. The types of measures reported, proportion of studies reporting ≥2 measures and mean (±SD) number of measures per study were determined for all studies and compared between subgroups. DATA EXTRACTION: Through the use of a standardised data extraction tool, we independently extracted all data, with disagreements resolved by a separate investigator. RESULTS: 148 studies were included, 57% of which reported ≥2 control measures (mean/study=2.13±1.36). The proportion of time spent in the target international normalised ratio range (TTR) was most commonly reported (79%), and was frequently accompanied by time above/below range (52%). AF studies more frequently reported ≥2 control measures compared with VTE studies (63% vs 37%; p=0.004), and reported a greater number of measures per study (mean=2.36 vs 1.53; p<0.001). Observational studies were more likely to provide ≥2 measures compared with randomised trials (76% vs 33%; p<0.001) and report a greater number of measures (mean=2.58 vs 1.63; p<0.001). More recent studies (2004–2013) reported ≥2 measures more often than older (2000–2003) studies (59% vs 35%; p=0.05) and reported more measures per study (mean=2.23 vs 1.48; p=0.02). CONCLUSIONS: While TTR was often utilised, studies reported ≥2 measures of VKA control only about half of the time and lacked consistency in the types of measures reported. A trend towards studies reporting greater numbers of VKA control measures over time was observed over our review time horizon, particularly, with AF and observational studies.
format Online
Article
Text
id pubmed-4067815
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-40678152014-06-25 Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review Mearns, Elizabeth S Hawthorne, Jessica Song, Ju-Sung Coleman, Craig I BMJ Open Cardiovascular Medicine OBJECTIVE: To aid trialists, systematic reviewers and others, we evaluated the degree of standardisation of control measure reporting that has occurred in atrial fibrillation (AF) and venous thromboembolism (VTE) studies since 2000; and attempted to determine whether the prior recommendation of reporting ≥2 measures per study has been employed. DESIGN: Systematic review. SEARCH STRATEGY: We searched bibliographic databases (2000 to June 2013) to identify AF and VTE studies evaluating dose-adjusted vitamin K antagonists (VKAs) and reporting ≥1 control measure. The types of measures reported, proportion of studies reporting ≥2 measures and mean (±SD) number of measures per study were determined for all studies and compared between subgroups. DATA EXTRACTION: Through the use of a standardised data extraction tool, we independently extracted all data, with disagreements resolved by a separate investigator. RESULTS: 148 studies were included, 57% of which reported ≥2 control measures (mean/study=2.13±1.36). The proportion of time spent in the target international normalised ratio range (TTR) was most commonly reported (79%), and was frequently accompanied by time above/below range (52%). AF studies more frequently reported ≥2 control measures compared with VTE studies (63% vs 37%; p=0.004), and reported a greater number of measures per study (mean=2.36 vs 1.53; p<0.001). Observational studies were more likely to provide ≥2 measures compared with randomised trials (76% vs 33%; p<0.001) and report a greater number of measures (mean=2.58 vs 1.63; p<0.001). More recent studies (2004–2013) reported ≥2 measures more often than older (2000–2003) studies (59% vs 35%; p=0.05) and reported more measures per study (mean=2.23 vs 1.48; p=0.02). CONCLUSIONS: While TTR was often utilised, studies reported ≥2 measures of VKA control only about half of the time and lacked consistency in the types of measures reported. A trend towards studies reporting greater numbers of VKA control measures over time was observed over our review time horizon, particularly, with AF and observational studies. BMJ Publishing Group 2014-06-20 /pmc/articles/PMC4067815/ /pubmed/24951111 http://dx.doi.org/10.1136/bmjopen-2014-005379 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Cardiovascular Medicine
Mearns, Elizabeth S
Hawthorne, Jessica
Song, Ju-Sung
Coleman, Craig I
Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review
title Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review
title_full Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review
title_fullStr Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review
title_full_unstemmed Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review
title_short Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review
title_sort measures of vitamin k antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067815/
https://www.ncbi.nlm.nih.gov/pubmed/24951111
http://dx.doi.org/10.1136/bmjopen-2014-005379
work_keys_str_mv AT mearnselizabeths measuresofvitaminkantagonistcontrolreportedinatrialfibrillationandvenousthromboembolismstudiesasystematicreview
AT hawthornejessica measuresofvitaminkantagonistcontrolreportedinatrialfibrillationandvenousthromboembolismstudiesasystematicreview
AT songjusung measuresofvitaminkantagonistcontrolreportedinatrialfibrillationandvenousthromboembolismstudiesasystematicreview
AT colemancraigi measuresofvitaminkantagonistcontrolreportedinatrialfibrillationandvenousthromboembolismstudiesasystematicreview